Potential Side Effects of Vardenafil Treatment

Most insurance companies will not cover the cost of vardenafil because they don’t consider it medically necessary. Administration with nitrates and nitric oxide donors Administration with nitrates and nitric oxide donors Administration with guanylate cyclase (GC) stimulators, such as riociguat Administration with guanylate cyclase (GC) stimulators, such as riociguat Cardiovascular effects: Patients should not use vardenafil hydrochloride if sex is inadvisable due to cardiovascular status Cardiovascular effects: Patients should not use vardenafil hydrochloride if sex is inadvisable due to cardiovascular status Risk of prolonged erection: In the event that an erection lasts more than 4 hours, the patient should seek immediate medical assistance Risk of prolonged erection: In the event that an erection lasts more than 4 hours, the patient should seek immediate medical assistance Effects on the eye: Patients should stop use of vardenafil hydrochloride and seek medical attention in the event of sudden loss of vision in one or both eyes, which could be a sign of nonarteritic anterior ischemic optic neuropathy (NAION) Effects on the eye: Patients should stop use of vardenafil hydrochloride and seek medical attention in the event of sudden loss of vision in one or both eyes, which could be a sign of nonarteritic anterior ischemic optic neuropathy (NAION) Sudden hearing loss: Patients should stop vardenafil hydrochloride and seek medical attention in the event of sudden decrease or loss in hearing Sudden hearing loss: Patients should stop vardenafil hydrochloride and seek medical attention in the event of sudden decrease or loss in hearing Alpha-blockers: Caution is advised when PDE5 inhibitors are co-administered with alpha-blockers Alpha-blockers: Caution is advised when PDE5 inhibitors are co-administered with alpha-blockers QT prolongation: Patients with congenital QT syndrome or taking class IA or III antiarrhythmics should avoid using vardenafil hydrochloride QT prolongation: Patients with congenital QT syndrome or taking class IA or III antiarrhythmics should avoid using vardenafil hydrochloride The typical vardenafil dose is 10 mg, but the medication is also available in 2.5 mg, 5 mg, and 20 mg doses. Your healthcare provider can help you decide which dose is best for you. Although early clinical trials show that vardenafil is more potent than Viagra’s active ingredient, sildenafil, both medications were deemed similarly effective in treating ED. The half-life of vardenafil is four to five hours, meaning it effectively relieves ED for an average of five hours at a time, but it’s most effective in the first few hours after you’ve taken it. *This information is from the vardenafil hydrochloride label used by Teva Pharmaceuticals USA, Inc.

Erectile Dysfunction: Oral Therapy Treatment Options

Most insurance companies will not cover the cost of vardenafil because they don’t consider it medically necessary. Administration with nitrates and nitric oxide donors Administration with nitrates and nitric oxide donors Administration with guanylate cyclase (GC) stimulators, such as riociguat Administration with guanylate cyclase (GC) stimulators, such as riociguat Cardiovascular effects: Patients should not use vardenafil hydrochloride if sex is inadvisable due to cardiovascular status Cardiovascular effects: Patients should not use vardenafil hydrochloride if sex is inadvisable due to cardiovascular status Risk of prolonged erection: In the event that an erection lasts more than 4 hours, the patient should seek immediate medical assistance Risk of prolonged erection: In the event that an erection lasts more than 4 hours, the patient should seek immediate medical assistance Effects on the eye: Patients should stop use of vardenafil hydrochloride and seek medical attention in the event of sudden loss of vision in one or both eyes, which could be a sign of nonarteritic anterior ischemic optic neuropathy (NAION) Effects on the eye: Patients should stop use of vardenafil hydrochloride and seek medical attention in the event of sudden loss of vision in one or both eyes, which could be a sign of nonarteritic anterior ischemic optic neuropathy (NAION) Sudden hearing loss: Patients should stop vardenafil hydrochloride and seek medical attention in the event of sudden decrease or loss in hearing Sudden hearing loss: Patients should stop vardenafil hydrochloride and seek medical attention in the event of sudden decrease or loss in hearing Alpha-blockers: Caution is advised when PDE5 inhibitors are co-administered with alpha-blockers Alpha-blockers: Caution is advised when PDE5 inhibitors are co-administered with alpha-blockers QT prolongation: Patients with congenital QT syndrome or taking class IA or III antiarrhythmics should avoid using vardenafil hydrochloride QT prolongation: Patients with congenital QT syndrome or taking class IA or III antiarrhythmics should avoid using vardenafil hydrochloride The typical vardenafil dose is 10 mg, but the medication is also available in 2.5 mg, 5 mg, and 20 mg doses. Your healthcare provider can help you decide which dose is best for you. Although early clinical trials show that vardenafil is more potent than Viagra’s active ingredient, sildenafil, both medications were deemed similarly effective in treating ED. The half-life of vardenafil is four to five hours, meaning it effectively relieves ED for an average of five hours at a time, but it’s most effective in the first few hours after you’ve taken it.

Outcome and Management

*This information is from the vardenafil hydrochloride label used by Teva Pharmaceuticals USA, Inc. See the Full Prescribing Information for more complete information. Vardenafil may be the active ingredient in other medications, and this information may not be accurate for all medications that include the active ingredient vardenafil. This article is for informational purposes only and does not constitute medical advice. The information contained herein is not a substitute for and should never be relied upon for professional medical advice. See the Full Prescribing Information for more complete information. Vardenafil may be the active ingredient in other medications, and this information may not be accurate for all medications that include the active ingredient vardenafil. This article is for informational purposes only and does not constitute medical advice.

Product	Dosage	Quantity + Bonus	Price
Tadalista Super Active	20mg	90 + 10 Pills	314.14€ 299.18€	Buy
Viagra Generic	150mg	20 Pills	55.02€ 52.40€	Buy
Kamagra Polo	100mg	20 Pills	83.56€ 79.58€	Buy
Cialis Generic	60mg	180 + 10 Pills	313.11€ 298.20€	Buy
Cialis Generic	40mg	10 Pills	37.79€ 35.99€	Buy
Kamagra Polo	100 mg	32 Pills	125.88€ 119.89€	Buy
Levitra Generic	40mg	10 Pills	41.37€ 39.40€	Buy
Viagra Generic	50mg	360 + 10 Pills	225.33€ 214.60€	Buy
Cialis Generic	2.5mg	270 + 10 Pills	199.64€ 190.13€	Buy
Viagra Original	100mg	92 + 4 Pills	362.88€ 345.60€	Buy
Cialis Super Active	20mg	180 + 20 Pills	521.59€ 496.75€	Buy

The information contained herein is not a substitute for and should never be relied upon for professional medical advice.

Point	Explanation	Key Advice
Take on an empty stomach or light meal	Food may delay absorption but not reduce efficacy	Take at least 30 minutes before activity
Do not exceed prescribed dose	Risk of side effects	Follow doctor's instructions
Seek medical help for prolonged erection (>4 hours)	Urological emergency	Immediate medical attention
Inform doctor of other medications	To avoid interactions	Full medication list

Always talk to your doctor about the risks and benefits of any treatment. Learn more about our editorial standards here. All trademarks are the property of their respective owners.

• Storage should be at room temperature away from moisture.
• Keep Vardenafil out of reach of children and pets.
• Check expiration date before use.

Use of third-party trademarks is for informational purposes only and does not imply endorsement or affiliation with Hims, Inc. Vardenafilhydrochloride tablets are a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction. Vardenafilis taken as needed: For most patients, the starting dose is 10 mg, up to once daily. Increase to 20 mg or decrease to 5 mg based on efficacy/tolerability. A starting dose of 5 mg vardenafilhydrochloride tablets should be considered in patients ≥ 65 years of age. Vardenafilis taken orally, approximately 60 minutes before sexual activity. The maximum recommended dosing frequency is one tablet per day.

• Vardenafil can interact with nitrates causing dangerous drops in blood pressure.
• Inform your doctor about all medications before use.
• Avoid alcohol while taking Vardenafil to reduce side effects.

If taking strong or moderate inhibitors of CYP3A4, the dose of Vardenafilhydrochloride tablets should be adjusted as follows (2.4, 5.2, 7.2): In patients on stable alpha-blocker therapy the recommended starting dose of vardenafil hydrochlorideis 5 mg (2.4, 5.6) The recommended starting dose of vardenafilis 5 mg in patients with moderate hepatic impairment (Child-Pugh B). The maximum dose in patients with moderate hepatic impairment should not exceed 10 mg. (2.3, 8.6) If taking strong or moderate inhibitors of CYP3A4, the dose of vardenafil hydrochloride tablets should be adjusted as follows: • Ritonavir: No more than 2.5 mg in a 72-hour period • Indinavir, saquinavir, atazanavir, ketoconazole 400 mg daily, itraconazole 400 mg daily, clarithromycin: No more than 2.5 mg in a 24-hour period • Ketoconazole 200 mg daily, itraconazole 200 mg daily, erythromycin: No more than 5 mg in a 24-hour period.

What side effects can this medication cause?

Three clinical pharmacology studies were conducted in patients with benign prostatic hyperplasia (BPH) on stable-dose alpha-blocker treatment, consisting of alfuzosin, tamsulosin or terazosin. The patient population included men aged 40-80 years with stable exercise-induced angina documented by at least one of the following: 1) prior history of myocardial infarction (MI), coronary artery bypass graft (CABG), percutaneous transluminal coronary angioplasty (PTCA), or stenting (not within 6 months); 2) positive coronary angiogram showing at least 60% narrowing of the diameter of at least one major coronary artery; or 3) a positive stress echocardiogram or stress nuclear perfusion study. In a single dose study in 25 normal males, vardenafil hydrochloride tablets 40 mg, twice the maximum daily recommended dose, did not alter visual acuity, intraocular pressure, fundoscopic and slit lamp findings. The total body clearance of vardenafil is 56 L/h, and the terminal half-life of vardenafil and its primary metabolite (M1) is approximately 4 to 5 hours. After oral administration, vardenafil is excreted as metabolites predominantly in the feces (approximately 91 to 95% of administered oral dose) and to a lesser extent in the urine (approximately 2 to 6% of administered oral dose). Vardenafilhydrochloride tablets 2.5 mg, 5 mg, 10 mg, 20 mg (3) Administration with nitrates and nitric oxide donors (2.4, 4.1) Administration with guanylate cyclase (GC) stimulators, such as riociguat (2.4, 4.2) Cardiovascular Effects: Patients should not use vardenafilhydrochloride tablets if sex is inadvisable due to cardiovascular status.

• Vardenafil is a medication used to treat erectile dysfunction.
• It works by relaxing blood vessels in the penis.
• Vardenafil is sold under brand names like Levitra.

Risk of Priapism: In the event that an erection lasts more than 4 hours, the patient should seek immediate medical assistance. (5.3)Effects on the Eye:Patients should stop use of vardenafilhydrochloride tablets, super p force 160mg and seek medical attention in the event of sudden loss of vision in one or both eyes, which could be a sign of nonarteritic anterior ischemic optic neuropathy (NAION). Vardenafil hydrochloride tablets should be used with caution, and only when the anticipated benefits outweigh the risks, in patients with a history of NAION.

Side Effects

If taking strong or moderate inhibitors of CYP3A4, the dose of Vardenafilhydrochloride tablets should be adjusted as follows (2.4, 5.2, 7.2): In patients on stable alpha-blocker therapy the recommended starting dose of vardenafil hydrochlorideis 5 mg (2.4, 5.6) The recommended starting dose of vardenafilis 5 mg in patients with moderate hepatic impairment (Child-Pugh B). The maximum dose in patients with moderate hepatic impairment should not exceed 10 mg. (2.3, 8.6) If taking strong or moderate inhibitors of CYP3A4, the dose of vardenafil hydrochloride tablets should be adjusted as follows: • Ritonavir: No more than 2.5 mg in a 72-hour period • Indinavir, saquinavir, atazanavir, ketoconazole 400 mg daily, itraconazole 400 mg daily, clarithromycin: No more than 2.5 mg in a 24-hour period • Ketoconazole 200 mg daily, itraconazole 200 mg daily, erythromycin: No more than 5 mg in a 24-hour period. Vardenafilhydrochloride tablets 2.5 mg, 5 mg, 10 mg, 20 mg (3) Administration with nitrates and nitric oxide donors (2.4, 4.1) Administration with guanylate cyclase (GC) stimulators, such as riociguat (2.4, 4.2) Cardiovascular Effects: Patients should not use vardenafilhydrochloride tablets if sex is inadvisable due to cardiovascular status. Risk of Priapism: In the event that an erection lasts more than 4 hours, the patient should seek immediate medical assistance.

Do you need a prescription for Levitra or generic vardenafil?

(5.3)Effects on the Eye:Patients should stop use of vardenafilhydrochloride tablets, super p force 160mg and seek medical attention in the event of sudden loss of vision in one or both eyes, which could be a sign of nonarteritic anterior ischemic optic neuropathy (NAION). Vardenafil hydrochloride tablets should be used with caution, and only when the anticipated benefits outweigh the risks, in patients with a history of NAION. Patients with a “crowded” optic disc may also be at an increased risk of NAION. Effects on the Eye:Patients should stop use of vardenafilhydrochloride tablets, and seek medical attention in the event of sudden loss of vision in one or both eyes, which could be a sign of nonarteritic anterior ischemic optic neuropathy (NAION). Sudden Hearing Loss: Patients should stop vardenafilhydrochloride tablets and seek medical attention in the event of sudden decrease or loss in hearing. Patients with a “crowded” optic disc may also be at an increased risk of NAION. Effects on the Eye:Patients should stop use of vardenafilhydrochloride tablets, and seek medical attention in the event of sudden loss of vision in one or both eyes, which could be a sign of nonarteritic anterior ischemic optic neuropathy (NAION). Sudden Hearing Loss: Patients should stop vardenafilhydrochloride tablets and seek medical attention in the event of sudden decrease or loss in hearing. Alpha-Blockers: Caution is advised when PDE5 inhibitors are coadministered with alpha-blockers. In some patients, concomitant use of these two drug classes can lower blood pressure significantly leading to symptomatic hypotension (for example, fainting). QT Prolongation: Patients with congenital QT syndrome or taking class IA or III antiarrhythmics should avoid using vardenafilhydrochloride tablets. Patients should be stable on alpha-blocker therapy prior to initiating a PDE5 inhibitor. In those patients who are stable on alpha-blocker therapy, PDE5 inhibitors should be initiated at the lowest recommended starting dose [see Dosage and Administration (.2.4)] In those patients already taking an optimized dose of PDE5 inhibitor, alpha-blocker therapy should be initiated at the lowest dose. Cardiovascular Effects [see Contraindications (4.1) and Warnings and Precautions (5.1)] Priapism [see Warnings and Precautions (5.3)] Effects on Eye [see Warnings and Precautions (5.4)] Sudden Hearing Loss [see Warnings and Precautions (5.5)] QT Prolongation [see Warnings and Precautions (5.7)] Placebo-controlled trials suggested a dose effect in the incidence of some adverse reactions (headache, flushing, dyspepsia, nausea, and rhinitis) over the 5 mg, 10 mg, and 20 mg doses of vardenafil hydrochloride tablets. Vardenafilhydrochloride tablets can potentiate the hypotensive effects of nitrates, alpha-blockers, and antihypertensives. Vardenafilis not indicated for use in pediatric patients. Do not use vardenafilhydrochloride tablets in patients with severe hepatic impairment (Child-Pugh C). Do not use vardenafil hydrochloride tablets in patients on renal dialysis. Vardenafil hydrochloride tablets are not indicated for use in females.

Medical uses

Always talk to your doctor about the risks and benefits of any treatment. Learn more about our editorial standards here. All trademarks are the property of their respective owners. Use of third-party trademarks is for informational purposes only and does not imply endorsement or affiliation with Hims, Inc. Vardenafilhydrochloride tablets are a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction.

SOP Conservative (Medical and Mechanical) Treatment of Erectile Dysfunction

Vardenafilis taken as needed: For most patients, the starting dose is 10 mg, up to once daily. Increase to 20 mg or decrease to 5 mg based on efficacy/tolerability. A starting dose of 5 mg vardenafilhydrochloride tablets should be considered in patients ≥ 65 years of age. Vardenafilis taken orally, approximately 60 minutes before sexual activity. The maximum recommended dosing frequency is one tablet per day. There are no data with the use of Vardenafil hydrochloride tablets in pregnant women to inform any drug-associated risks. reproduction studies conducted in pregnant rats and rabbits, no adverse developmental outcomes were observed with oral administration of vardenafil during organogenesis at exposures for unbound vardenafil and its major metabolite at approximately 100 and 29 times, respectively, MRHD of 20 mg based on AUC(see Data).

• Vardenafil enhances blood flow to help achieve an erection.
• It does not cause automatic erections without sexual stimulation.
• Does not protect against sexually transmitted infections.

There is no information on the presence of vardenafil and its major metabolite in human milk, the effects on the breastfed infant, or the effects on milk production. Vardenafil is present in rat milk of lactating rats ( Vardenafil was secreted into the milk of lactating rats at concentrations approximately 10-fold greater than found in the plasma. Three clinical pharmacology studies were conducted in patients with benign prostatic hyperplasia (BPH) on stable-dose alpha-blocker treatment, consisting of alfuzosin, tamsulosin or terazosin. The patient population included men aged 40-80 years with stable exercise-induced angina documented by at least one of the following: 1) prior history of myocardial infarction (MI), coronary artery bypass graft (CABG), percutaneous transluminal coronary angioplasty (PTCA), or stenting (not within 6 months); 2) positive coronary angiogram showing at least 60% narrowing of the diameter of at least one major coronary artery; or 3) a positive stress echocardiogram or stress nuclear perfusion study.

Form Type	Dosage Range (mg)	Available Brands	Typical Use Duration
Tablets	2.5, 5, 10, 20	Levitra, Staxyn	Up to 4-6 hours
Orally Disintegrating Tablets	10	Levitra ODT	Up to 4 hours
Sublingual Tablets	10	Staxyn	Up to 4 hours

In a single dose study in 25 normal males, vardenafil hydrochloride tablets 40 mg, twice the maximum daily recommended dose, did not alter visual acuity, intraocular pressure, fundoscopic and slit lamp findings.

Adverse reactions

Vardenafil hydrochloride tablets are not indicated for use in females. There are no data with the use of Vardenafil hydrochloride tablets in pregnant women to inform any drug-associated risks. reproduction studies conducted in pregnant rats and rabbits, no adverse developmental outcomes were observed with oral administration of vardenafil during organogenesis at exposures for unbound vardenafil and its major metabolite at approximately 100 and 29 times, respectively, MRHD of 20 mg based on AUC(see Data). There is no information on the presence of vardenafil and its major metabolite in human milk, the effects on the breastfed infant, or the effects on milk production. Vardenafil is present in rat milk of lactating rats ( Vardenafil was secreted into the milk of lactating rats at concentrations approximately 10-fold greater than found in the plasma. The total body clearance of vardenafil is 56 L/h, and the terminal half-life of vardenafil and its primary metabolite (M1) is approximately 4 to 5 hours. After oral administration, vardenafil is excreted as metabolites predominantly in the feces (approximately 91 to 95% of administered oral dose) and to a lesser extent in the urine (approximately 2 to 6% of administered oral dose).

What special precautions should I follow?

Alpha-Blockers: Caution is advised when PDE5 inhibitors are coadministered with alpha-blockers. In some patients, concomitant use of these two drug classes can lower blood pressure significantly leading to symptomatic hypotension (for example, fainting). QT Prolongation: Patients with congenital QT syndrome or taking class IA or III antiarrhythmics should avoid using vardenafilhydrochloride tablets. Patients should be stable on alpha-blocker therapy prior to initiating a PDE5 inhibitor. In those patients who are stable on alpha-blocker therapy, PDE5 inhibitors should be initiated at the lowest recommended starting dose [see Dosage and Administration (.2.4)] In those patients already taking an optimized dose of PDE5 inhibitor, alpha-blocker therapy should be initiated at the lowest dose.

How Long Do They Last?

Cardiovascular Effects [see Contraindications (4.1) and Warnings and Precautions (5.1)] Priapism [see Warnings and Precautions (5.3)] Effects on Eye [see Warnings and Precautions (5.4)] Sudden Hearing Loss [see Warnings and Precautions (5.5)] QT Prolongation [see Warnings and Precautions (5.7)] Placebo-controlled trials suggested a dose effect in the incidence of some adverse reactions (headache, flushing, dyspepsia, nausea, and rhinitis) over the 5 mg, 10 mg, and 20 mg doses of vardenafil hydrochloride tablets. Vardenafilhydrochloride tablets can potentiate the hypotensive effects of nitrates, alpha-blockers, and antihypertensives. Vardenafilis not indicated for use in pediatric patients. Do not use vardenafilhydrochloride tablets in patients with severe hepatic impairment (Child-Pugh C). Do not use vardenafil hydrochloride tablets in patients on renal dialysis.